Table 5 Major series reporting surgical management of hepatic metastases from gynaecological malignancies
First Author Year of Publication | Number of patients | Primary vs Recurrent Disease | Primary Site | Median overall survival (from time of liver resection unless otherwise stated) | Factors associated with longest survival |
|---|---|---|---|---|---|
Kolev [91] 2014 | 27 | Recurrent | Ovary | 12 months (2–190) | Interval from primary surgery of >24 months (P = 0.044) Secondary cytoreduction to <1 cm (P = 0.014) |
Neumann [82] 2012 | 41 | Primary | Ovary | R0 – 42 months R1 – 4 months R2 – 6 months | Post operative residual tumour mass |
Roh [77] 2011 | 18 | Recurrent | Ovary | 38 months (3–78) | Less abdominal than pelvic disease (38 vs 11 months, P = 0.032) Optimal cytoreduction (40 vs 9 months, P = 0.0004) Negative margin status of hepatic resection (40 vs (months, P = 0.0196 |
Kamel [92] 2011 | 52 | Primary | Ovary | 53Â months 5-year survival 41Â % | Not reported |
Knowles [93] 2010 | 5 | Recurrent | Endometrioid (Ovarian or Endometrial) | Median OS not reported DFS range 8–66 months | Not reported |
Lim [75] 2009 | 14 | Primary | Ovary | 5-year PFS by Stage: - IIIC – 25 % - IV – 23 % 5-year OS by Stage: - IIIC – 55 % - IV – 51 % | Not reported |
Loizzi [94] 2005 | 29 | Primary (Group 1) – 8 1st Recurrence (Group 2) – 10 2nd recurrence (Group 3) – 11 | Ovary | Median survival from time of liver metastasis diagnosis: Group 1 – 19 months Group 2 – 24 months Group 3 – 10 months | Cell type Performance status Number of hepatic lesions Presence of other sites of disease at time of diagnosis of hepatic metastasis Platinum based chemotherapy |
Weitz [76] 2005 | 19 | Recurrent | Ovary – 63.2 % Endometrium – 21.1 % Cervix – 10.5 % Fallopian tube – 5.2 % | Reproductive tract tumours (note – included testicular cancer pts, but no difference between ovary and testicular survival) Median cancer specific survival reproductive tract primary – 115 months Ovary - 3 year recurrence free survival 58 % | Primary tumour type Length of disease free interval from primary tumour |
Yoon [95] 2003 | 24 | Recurrent | Ovary Fallopian tube | 62 months (6–94) | No significant prognostic factors for OS identified on univariate analysis |
Merideth [89] 2003 | 26 | Recurrent | Ovary | Overall median disease-related survival 26.3 months | >12 months since original diagnosis (27.3 vs 5.7 months, P = 0.004) ≤1 cm residual disease (27.3 vs 8.6 months, P = 0.031) |
Fan [96] 2001 | 18 |  | Ovary – immature teratoma | 3-year survival – 77.8 % 5-year survival – 55.6 % 10-year survival – 38.9 % | Not reported |
Naik [97] 2000 | 37 | Primary | Ovary | 11 months 2-year survival 23 % 5-year survival 9 % | Optimal surgery with residual <2 cm (P = 0.0029) or <1 cm (P = 0.0086) |
Bristow [81] 1999 | 37 | Primary | Ovary | Optimal extrahepatic and hepatic resection – 50.1 months Optimal extrahepatic resection with residual hepatic tumour – 27.0 months Suboptimal with residual extrahepatic and heaptic tumour – 7.6 months | Optimal extrahepatic resection (P = 0.0001) |
Elias [84] 1998 | 6 | Not stated | Gynecologic | 5-year survival – 45 % | Not reported |
Chi [71] 1997 | 12 | Recurrent | Ovary – 58 % Cervix – 17 % Endometrium – 17 % Fallopian tube – 1 8 % | 27 months (Median f/up 25 months, range 8–94 months) | Not reported |